NCT03411421View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 3, 2018

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions
Healthy
Interventions
DRUG

AL-794

AL-794 will be administered as tablets orally on Day 1 to Day 5.

DRUG

Placebo

Matching placebo tablets will be administered.

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT03411421 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers | Biotech Hunter | Biotech Hunter